MedStar Authors catalog › Details for: Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study.
Normal view MARC view ISBD view

Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study.

by Najjar, Samer S.
Citation: Journal of Heart & Lung Transplantation. 2020 Mar 20.Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.Published: ; 2020ISSN: 1053-2498.Full author list: Saeed O; Colombo PC; Mehra MR; Uriel N; Goldstein DJ; Cleveland J; Conners JM; Najjar SS; Mokadam NA; Bansal A; Crandall DL; Sood P; Jorde UP.UI/PMID: 32340871.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access online Digital Object Identifier: https://dx.doi.org/10.1016/j.healun.2020.03.001 (Click here) Abbreviated citation: J Heart Lung Transplant. 2020 Mar 20.Local Holdings: Available online from MWHC library: 1999 - present, Available in print through MWHC library:1999-2007.Abstract: BACKGROUND: Aspirin (ASA) anti-platelet therapy is mandated with left ventricular assist devices (LVADs) to prevent hemocompatibility-related adverse events (HRAEs). However, the optimal dose of ASA with HeartMate 3 (HM3) LVAD is unknown.Abstract: METHODS: In an exploratory analysis of HM3-supported patients in the MOMENTUM 3 study (NCT02224755), 2 groups were analyzed: usual-dose (325 mg) and low-dose (81 mg) ASA with anti-coagulation targeted to an international normalized ratio of 2.0 to 3.0. Exclusion criteria included patients not receiving either ASA 81 mg or 325 mg, those with HRAEs <=7 days after device implantation, and those receiving >1 anti-platelet agent. The primary end-point was survival free from HRAEs (non-surgical bleeding, pump thrombosis, stroke, and peripheral arterial thromboembolic events) at 2 years.Abstract: RESULTS: Overall, 321 HM3 patients (usual-dose: n=141, low-dose: n=180) were included in this analysis. Usual-dose group patients were younger (57 +/- 13 vs 60 +/- 12 years, p=0.035) and less often assigned destination therapy (55% vs 67%, p=0.029) than low-dose ASA. At 2 years, a similar proportion of patients in the usual- and low-dose groups (43.4% vs 45.3%, p=0.94) met the primary end-point. There were no differences in survival free from hemorrhagic (usual-dose: 54.4% vs low-dose: 51.7%, p=0.42) or thrombotic (usual-dose: 76.8% vs low-dose: 75.7%, p=0.92) events.Abstract: CONCLUSIONS: Usual- and low-dose ASA revealed similar rates of bleeding and thrombotic events in HM3 LVAD-supported patients within the MOMENTUM 3 trial. Whether ASA therapy provides any meaningful therapeutic effect in patients treated by the HM3 LVAD remains to be determined. Copyright (c) 2020 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Powered by Koha